![]() |
|
![]() |
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
Sponsors and Collaborators: |
Dana-Farber Cancer Institute Brigham and Women's Hospital Breast Cancer Research Foundation GlaxoSmithKline |
Information provided by: | Dana-Farber Cancer Institute |
ClinicalTrials.gov Identifier: | NCT00470847 |
The purpose of this research study is to determine the safety of combining lapatinib plus radiation in patients with breast cancer that has spread to the brain. Depending upon the participants cancer, they may also have stereotactic radiosurgery (SRS). Lapatinib s a compound that may stop cancer cells from growing abnormally. It is thought that lapatinib might also make cancer cells more sensitive to radiation. This drug has been used in other research studies in women with breast cancer, and information from those other research studies suggests that lapatinib may help to shrink or stabilize breast tumors both inside the brain and outside the brain.
Condition | Intervention | Phase |
Breast Cancer Brain Metastases |
Drug: Lapatinib Procedure: Whole Brain Radiation |
Phase I |
Genetics Home Reference related topics: | breast cancer |
MedlinePlus related topics: | Breast Cancer Cancer |
ChemIDplus related topics: | Lapatinib Lapatinib Ditosylate Trastuzumab |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety Study |
Official Title: | A Phase I Study of Lapatinib in Combination With Radiation Therapy in Patients With Brain Metastases From HER2-Positive Breast Cancer |
Estimated Enrollment: | 39 |
Study Start Date: | April 2007 |
Estimated Study Completion Date: | January 2010 |
Estimated Primary Completion Date: | January 2010 (Final data collection date for primary outcome measure) |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Nancy Lin, MD | 617-632-5269 | nlin@partners.org |
Contact: Emily Eisenberg | 617-632-6930 | eeisenberg@partners.org |
United States, Indiana | |||||
Indiana University Melvin and Bren Simon Cancer Center | Recruiting | ||||
Indianapolis, Indiana, United States, 46202 | |||||
Contact: Anita Rush-Taylor, RN 317-278-6797 arushtay@iupui.edu | |||||
Principal Investigator: Anna Maria Storniolo, MD | |||||
United States, Massachusetts | |||||
Dana-Farber Cancer Institute | Recruiting | ||||
Boston, Massachusetts, United States, 02115 | |||||
Principal Investigator: Nancy Lin, MD | |||||
Sub-Investigator: Eric Winer, MD | |||||
Brigham and Women's Hospital | Recruiting | ||||
Boston, Massachusetts, United States, 02115 | |||||
Principal Investigator: Naren Ramakrishna, MD |
Dana-Farber Cancer Institute |
Brigham and Women's Hospital |
Breast Cancer Research Foundation |
GlaxoSmithKline |
Principal Investigator: | Nancy Lin, MD | Dana-Farber Cancer Institute |
Responsible Party: | Dana-Farber Cancer Institute ( Nancy Lin, MD ) |
Study ID Numbers: | 06-356 |
First Received: | May 7, 2007 |
Last Updated: | December 20, 2007 |
ClinicalTrials.gov Identifier: | NCT00470847 |
Health Authority: | United States: Institutional Review Board |
|
|
|
|
|
|
![]() |